世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

免疫療法用医薬品市場:薬品タイプ毎、疫学毎、エンドユーザ毎、地域毎 - 2021年までの世界市場予測

Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2017年1月US$5,650
シングルユーザライセンス
176 123

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の免疫療法用医薬品市場に関する調査レポートです。

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.  

In this report, the immunotherapy drugs market is segmented on the basis of type of drugs, therapy area, end user, and region. Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the immunotherapy drugs market.  However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of immunotherapy drugs market.

Based on type of drugs, the market is segmented into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others. Adult vaccines segment is further categorized into preventive vaccines and therapeutic vaccines. Monoclonal antibodies segment is expected to account for the largest market share in the immunotherapy drugs market, by type of drugs in 2016. On the other hand, checkpoint inhibitors segment is expected to be the fastest growing segment in the immunotherapy drugs market, by type of drugs, in 2016. The high growth of this segment can be attributed to factors such as increasing adoption of checkpoint inhibitors in cancer treatment with their ability to target only foreign cells leaving normal cells alone.

On the basis of therapy area, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Among these segments, the cancer segment is expected to account for the largest market share in 2016. Cancer segment is also expected to be the fastest growing segment in the immunotherapy drugs market, by therapy area in 2016. The large share and high growth of this segment can be attributed to factor such as high preference for immunotherapy as a first line of treatment in cancer leading to growing demand for immunotherapy drugs.

Based on geography, the immunotherapy drugs market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the immunotherapy drugs market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.

Acquisitions and new product approval was the most widely adopted growth strategy pursued by players in the immunotherapy drugs market, to increase their shares and cater to the unmet needs. The major players operating in the immunotherapy drugs market include F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.). Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.).

Research Coverage:

The report provides a picture immunotherapy drugs market across different industry verticals and regions. It aims at estimating the market size and future growth potential of this market across different segments such as type of drugs, therapy area, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Reasons to buy this report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.


The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios of the top players in the immunotherapy drugs market. The report provides an analysis of the immunotherapy drugs market, by treatment modality, application, and region

- Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the immunotherapy drugs market

- Market Development: Comprehensive information about lucrative emerging markets. This report provides an analysis of the immunotherapy drugs market across regions

- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global immunotherapy drugs market

- Competitive Assessment: In-depth assessment of market strategies, product portfolios, and manufacturing capabilities of the leading players in the global immunotherapy drugs market



目次

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.2.1 MARKETS COVERED 16
1.2.2 YEARS CONSIDERED FOR THE STUDY 16
1.3 CURRENCY 17
1.4 LIMITATIONS 17
1.5 STAKEHOLDERS 17

2 RESEARCH METHODOLOGY 18
2.1 MARKET SIZE ESTIMATION 19
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 22
2.3 MARKET SHARE ESTIMATION 23
2.3.1 KEY DATA FROM SECONDARY SOURCES 23
2.3.2 KEY DATA FROM PRIMARY SOURCES 24
2.3.3 ASSUMPTIONS FOR THE STUDY 24

3 EXECUTIVE SUMMARY 25
3.1 INTRODUCTION 25
3.2 CONCLUSION 29

4 PREMIUM INSIGHTS 30
4.1 GLOBAL IMMUNOTHERAPY DRUGS MARKET OVERVIEW 30
4.2 IMMUNOTHERAPY DRUGS MARKET: BY THERAPY AREA & REGION 30
4.3 IMMUNOTHERAPY DRUGS MARKET: GEOGRAPHIC SNAPSHOT 31
4.4 IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG 31
4.5 LIFE CYCLE ANALYSIS, BY REGION (2016) 32

5 MARKET OVERVIEW 33
5.1 INTRODUCTION 34
5.1.1 DRIVERS 35
5.1.1.1 Increasing Adoption of Targeted Therapy Over Traditional Therapy 35
5.1.1.2 Emergence of Biosimilars 35
5.1.1.3 Increasing Demand for mAbs 36
5.1.1.4 High Prevalence Rate of Lifestyle Diseases 36
5.1.1.5 Fast Track and Orphan Drug Designations 36
5.1.2 RESTRAINTS 37
5.1.2.1 High Cost of Immunotherapy Treatment 37
5.1.2.2 High Attrition Rate in the Product Development Cycle 37
5.1.3 OPPORTUNITIES 38
5.1.3.1 Emerging Markets 38
5.1.3.2 Immunotherapy to Replace Chemotherapy in Cancer Treatment 38
5.1.4 CHALLENGE 38
5.1.4.1 Impending Patent Expiry of Top-selling Biologics 38

6 INDUSTRY INSIGHTS 39
6.1 INTRODUCTION 39
6.2 EPIDEMIOLOGY COVERAGE 39
6.2.1 CANCER EPIDEMIOLOGY 39
6.2.2 AUTOIMMUNE DISEASE EPIDEMIOLOGY 40
6.3 PRICING AND REIMBURSEMENT SCENARIO 41
6.3.1 U.S. 42
6.3.2 U.K. 43
6.3.3 FRANCE 43
6.3.4 GERMANY 43
6.3.5 OTHER EUROPEAN COUNTRIES 43
6.3.6 JAPAN 43
6.4 RESEARCH FUNDING & GOVERNMENT INITIATIVES 44
6.5 PIPELINE DRUGS 45
6.5.1 PHASE 1 45
6.5.2 PHASE I/II 51
6.5.3 PHASE II 53
6.5.4 PHASE II/III 58
6.5.5 PHASE III 58
6.5.6 APPLICATION SUBMITTED 61
6.5.7 PROMISING MOLECULES 61
6.6 INDUSTRY TRENDS 63
6.7 KEY PRODUCTS EXPECTED TO BE LAUNCHED 64
6.8 TREATMENT PROTOCOLS AND LINE OF THERAPIES 65
6.8.1 FIRST-LINE THERAPY 65
6.8.2 SECOND-LINE THERAPY 65
6.8.3 OTHER TREATMENTS 65
6.9 BURNING ISSUES 66

7 IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG 67
7.1 INTRODUCTION 68
7.2 MONOCLONAL ANTIBODIES 69
7.3 ADULT VACCINES 70
7.3.1 PREVENTIVE VACCINES 72
7.3.2 THERAPEUTIC VACCINES 73
7.4 CHECKPOINT INHIBITORS 74
7.5 INTERFERONS ALPHA & BETA 75
7.6 INTERLEUKINS 76
7.7 OTHER DRUGS 77

8 IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA 79
8.1 INTRODUCTION 80
8.2 CANCER 81
8.3 AUTOIMMUNE AND INFLAMMATORY DISEASES 84
8.4 INFECTIOUS DISEASES 85
8.5 OTHER THERAPY AREAS 87

9 IMMUNOTHERAPY DRUGS MARKET, BY END USER 88
9.1 INTRODUCTION 89
9.2 HOSPITALS 90
9.3 CLINICS 91
9.4 OTHER END USERS 92

10 IMMUNOTHERAPY DRUGS MARKET, BY REGION 93
10.1 INTRODUCTION 94
10.2 NORTH AMERICA 96
10.2.1 U.S. 100
10.2.2 CANADA 102
10.3 EUROPE 105
10.3.1 GERMANY 108
10.3.2 U.K. 108
10.3.3 FRANCE 109
10.3.4 ITALY 109
10.3.5 SPAIN 109
10.4 ASIA-PACIFIC 110
10.4.1 JAPAN 113
10.4.2 CHINA 113
10.4.3 INDIA 113
10.5 REST OF THE WORLD (ROW) 114

11 COMPETITIVE LANDSCAPE 116
11.1 INTRODUCTION 116
11.2 STRATEGIC ANALYSIS 116
11.3 MARKET SHARE ANALYSIS 117
11.4 COMPETITIVE SITUATION AND TRENDS 118
11.4.1 REGULATORY APPROVALS 119
11.4.2 COLLABORATIONS 120
11.4.3 AGREEMENTS 121
11.4.4 ACQUISITIONS 122
11.4.5 EXPANSIONS 123

12 COMPANY PROFILES 124
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 INTRODUCTION 124
12.2 F. HOFFMANN-LA ROCHE AG 125
12.3 MERCK & CO., INC. 128
12.4 NOVARTIS INTERNATIONAL AG 132
12.5 JOHNSON & JOHNSON (A PARENT COMPANY OF JANSSEN BIOTECH, INC.) 135
12.6 GLAXOSMITHKLINE PLC 138
12.7 AMGEN INC. 141
12.8 ABBVIE 145
12.9 ASTRAZENECA 148
12.10 BRISTOL-MYERS SQUIBB 151
12.11 ELI LILLY AND COMPANY 154

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13 APPENDIX 157
13.1 INSIGHTS OF INDUSTRY EXPERTS 157
13.2 DISCUSSION GUIDE 158
13.3 OTHER DEVELOPMENTS 160
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 168
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 170
13.6 AVAILABLE CUSTOMIZATIONS 172
13.7 RELATED REPORTS 173
13.8 AUTHOR DETAILS 174


LIST OF TABLES

TABLE 1 IMMUNOTHERAPY DRUGS MARKET SUMMARY 25
TABLE 2 COMPARISON OF COST (BRANDED VS BIOSIMILAR VERSION) 35
TABLE 3 CANCER: ESTIMATED INCIDENCE, MORTALITY IN MEN (2015) 39
TABLE 4 CANCER: ESTIMATED INCIDENCE, MORTALITY IN WOMEN (2015) 40
TABLE 5 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG,
2014-2021 (USD BILLION) 68
TABLE 6 GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION,
2014-2021 (USD BILLION) 69
TABLE 7 NORTH AMERICA: MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY,
2014-2021 (USD BILLION) 70
TABLE 8 GLOBAL ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION) 71
TABLE 9 GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION) 71
TABLE 10 NORTH AMERICA: ADULT VACCINES MARKET SIZE, BY COUNTRY,
2014-2021 (USD BILLION) 71
TABLE 11 GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY REGION,
2014-2021 (USD BILLION) 72
TABLE 12 NORTH AMERICA: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY,
2014-2021 (USD BILLION) 72
TABLE 13 GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION,
2014-2021 (USD BILLION) 73
TABLE 14 NORTH AMERICA: THERAPEUTIC VACCINES MARKET SIZE,
BY COUNTRY, 2014-2021 (USD BILLION) 73
TABLE 15 GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION,
2014-2021 (USD BILLION) 74
TABLE 16 NORTH AMERICA: CHECKPOINT INHIBITORS MARKET SIZE,
BY COUNTRY, 2014-2021 (USD BILLION) 74
TABLE 17 GLOBAL INTERFERONS ALPHA & BETA MARKET SIZE,
BY REGION, 2014-2021 (USD BILLION) 75
TABLE 18 NORTH AMERICA: INTERFERONS ALPHA & BETA MARKET SIZE,
BY COUNTRY, 2014-2021 (USD BILLION) 75
TABLE 19 GLOBAL OTHER DRUGS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION) 77
TABLE 20 NORTH AMERICA: OTHER DRUGS MARKET SIZE, BY COUNTRY,
2014-2021 (USD BILLION) 78
TABLE 21 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA,
2014-2021 (USD BILLION) 80
TABLE 22 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE,
2014-2021 (USD BILLION) 81
TABLE 23 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY REGION,
2014-2021 (USD BILLION) 81
TABLE 24 NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY COUNTRY, 2014-2021 (USD BILLION) 82
TABLE 25 GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE FOR SOLID TUMORS,
BY REGION, 2014-2021 (USD BILLION) 82
TABLE 26 NORTH AMERICA: GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE FOR SOLID TUMORS, BY COUNTRY, 2014-2021 (USD BILLION) 82
TABLE 27 GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE FOR MALIGNANT TUMORS, BY REGION, 2014-2021 (USD BILLION) 83
TABLE 28 NORTH AMERICA: GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE FOR MALIGNANT TUMORS, BY COUNTRY, 2014-2021 (USD BILLION) 83
TABLE 29 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR AUTOIMMUNE AND INFLAMMATORY DISEASES, BY REGION, 2014-2021 (USD BILLION) 84
TABLE 30 NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR AUTOIMMUNE AND INFLAMMATORY DISEASES, BY COUNTRY,
2014-2021 (USD BILLION) 85
TABLE 31 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR INFECTIOUS DISEASES,
BY REGION, 2014-2021 (USD BILLION) 86
TABLE 32 NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY, 2014-2021 (USD BILLION) 86
TABLE 33 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR OTHER THERAPY AREAS,
BY REGION, 2014-2021 (USD BILLION) 87
TABLE 34 NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR OTHER THERAPY AREAS, BY COUNTRY, 2014-2021 (USD BILLION) 87
TABLE 35 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER,
2014-2021 (USD BILLION) 89
TABLE 36 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR HOSPITALS,
BY REGION, 2014-2021 (USD BILLION) 90
TABLE 37 NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2014-2021 (USD BILLION) 90
TABLE 38 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CLINICS, BY REGION,
2014-2021 (USD BILLION) 91
TABLE 39 NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CLINICS, BY COUNTRY, 2014-2021 (USD BILLION) 91
TABLE 40 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR OTHER END USERS,
BY REGION, 2014-2021 (USD BILLION) 92
TABLE 41 NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR OTHER END USERS, BY COUNTRY, 2014-2021 (USD BILLION) 92
TABLE 42 GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION,
2014-2021 (USD BILLION) 95
TABLE 43 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY,
2014-2021 (USD BILLION) 96
TABLE 44 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2014-2021 (USD BILLION) 98
TABLE 45 NORTH AMERICA: ADULT VACCINES MARKET SIZE, BY TYPE,
2014-2021 (USD BILLION) 99
TABLE 46 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA, 2014-2021 (USD BILLION) 99
TABLE 47 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE, 2014-2021 (USD BILLION) 99
TABLE 48 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER,
2014-2021 (USD BILLION) 100
TABLE 49 U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG,
2014-2021 (USD BILLION) 101
TABLE 50 U.S.: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION) 101
TABLE 51 THE U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA,
2014-2021 (USD BILLION) 101
TABLE 52 U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE,
2014-2021 (USD BILLION) 102
TABLE 53 THE U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER,
2014-2021 (USD BILLION) 102
TABLE 54 CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG,
2014-2021 (USD BILLION) 103
TABLE 55 CANADA: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION) 103
TABLE 56 CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA,
2014-2021 (USD BILLION) 104
TABLE 57 CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE,
2014-2021 (USD BILLION) 104
TABLE 58 CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER,
2014-2021 (USD BILLION) 104
TABLE 59 EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG,
2014-2021 (USD BILLION) 105
TABLE 60 EUROPE: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION) 107
TABLE 61 EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA,
2014-2021 (USD BILLION) 107
TABLE 62 EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE,
2014-2021 (USD BILLION) 108
TABLE 63 EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER,
2014-2021 (USD BILLION) 108
TABLE 64 APAC.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG,
2014-2021 (USD BILLION) 110
TABLE 65 APAC: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION) 112
TABLE 66 APAC: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA,
2014-2021 (USD BILLION) 112
TABLE 67 APAC: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE,
2014-2021 (USD BILLION) 112
TABLE 68 APAC: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER,
2014-2021 (USD BILLION) 113
TABLE 69 ROW: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG,
2014-2021 (USD BILLION) 114
TABLE 70 ROW: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION) 114
TABLE 71 ROW: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA,
2014-2021 (USD BILLION) 115
TABLE 72 ROW: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE,
2014-2021 (USD BILLION) 115
TABLE 73 ROW: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER,
2014-2021 (USD BILLION) 115
TABLE 74 MARKET DEVELOPMENTS, 2013-2016 118
TABLE 75 APPROVALS, 2013-2016 119
TABLE 76 COLLABORATIONS, 2013-2016 120
TABLE 77 AGREEMENTS, 2013-2016 121
TABLE 78 ACQUISITIONS, 2013-2016 122
TABLE 79 EXPANSIONS, 2013-2016 123


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 18
FIGURE 2 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 20
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 20
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 21
FIGURE 5 DATA TRIANGULATION METHODOLOGY 22
FIGURE 6 IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG,
2016 VS. 2021 (USD BILLION) 26
FIGURE 7 IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA,
2016 VS. 2021 (USD BILLION) 26
FIGURE 8 IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER,
2016 VS. 2021 (USD BILLION) 27
FIGURE 9 IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2016 28
FIGURE 10 IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION,
2016 VS. 2021 (USD BILLION) 28
FIGURE 11 INCREASING ADOPTION OF TARGET THERAPY OVER TRADITIONAL THERAPY TO DRIVE MARKET GROWTH 30
FIGURE 12 CANCER TO COMMAND THE LARGEST MARKET SHARE IN 2016 30
FIGURE 13 ASIA TO REGISTER HIGHEST GROWTH DURING THE FORECAST PERIOD 31
FIGURE 14 CHECKPOINT INHIBITORS EXPECTED TO BE THE FASTEST-GROWING SEGMENT 31
FIGURE 15 ASIA PRESENTS LUCRATIVE GROWTH OPPORTUNITIES IN THE IMMUNOTHERAPY DRUGS MARKET 32
FIGURE 16 INCREASING ADOPTION OF TARGETED THERAPY OVER TRADITIONAL THERAPY WILL DRIVE THE IMMUNOTHERAPY DRUGS MARKET 34
FIGURE 17 RISE IN COSTS OF CANCER IMMUNOTHERAPY DRUGS 37
FIGURE 18 PERCENTAGE OF ADULT POPULATION DIAGNOSED WITH AUTOIMMUNE DISEASES (OCTOBER 2016) 41
FIGURE 19 CANCER RESEARCH FUNDING IN 2014 45
FIGURE 20 CLINICAL PHASES OF PRODUCTS TO BE LAUNCHED 64
FIGURE 21 MONOCLONAL ANTIBODIES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016 68
FIGURE 22 PREVENTIVE VACCINES TO ACCOUNT FOR THE LARGEST SHARE IN 2016 70
FIGURE 23 GLOBAL INTERLEUKINS MARKET SIZE, 2016-2021 (USD BILLION) 76
FIGURE 24 CANCER ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016 80
FIGURE 25 HOSPITALS TO DOMINATE THE IMMUNOTHERAPY DRUGS MARKET,
BY END USER, DURING 2016-2021 89
FIGURE 26 GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC, THE FASTEST-GROWING REGION IN
2016-2021 94
FIGURE 27 CHECKPOINT INHIBITORS SEGMENT TO WITNESS HIGH GROWTH IN THE NORTH AMERICAN AND ASIA-PACIFIC MARKETS 95
FIGURE 28 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT 97
FIGURE 29 U.S. TO DOMINATE THE NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET 98
FIGURE 30 EUROPE: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT 106
FIGURE 31 APAC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT 111
FIGURE 32 KEY DEVELOPMENTS IN THE IMMUNOTHERAPY DRUGS MARKET, 2013-2016 116
FIGURE 33 IMMUNOTHERAPY DRUGS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015 117
FIGURE 34 GEOGRAPHIC REVENUE MIX OF THE TOP FIVE MARKET PLAYERS 124
FIGURE 35 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT 125
FIGURE 36 MERCK & CO., INC.: COMPANY SNAPSHOT 128
FIGURE 37 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT 132
FIGURE 38 JOHNSON & JOHNSON: COMPANY SNAPSHOT 135
FIGURE 39 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT 138
FIGURE 40 AMGEN INC.: COMPANY SNAPSHOT 141
FIGURE 41 ABBVIE: COMPANY SNAPSHOT 145
FIGURE 42 ASTRAZENECA: COMPANY SNAPSHOT 148
FIGURE 43 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT 151
FIGURE 44 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 154
 

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る